Archimedes Pharma to acquire Link Pharmaceuticals Group
Archimedes Pharma, the European specialty pharmaceutical company, has acquired Link Holdings, a UK-based pharmaceuticals group that focuses on sales and marketing of specialty pharmaceuticals with commercial operations in the UK, France and Germany.
Archimedes Pharma, the European specialty pharmaceutical company, has acquired Link Holdings, a UK-based pharmaceuticals group that focuses on sales and marketing of specialty pharmaceuticals with commercial operations in the UK, France and Germany.
Link is on track to record revenues of approximately £16m in 2006, showing steady growth. Link will become the UK commercial organisation for Archimedes whilst the French and German operations will form the basis of Archimedes' European commercial operations. Financial terms were not disclosed.
The acquisition of Link brings Archimedes a commercial infrastructure of around 40 people to add to its existing organisation. The current customer base targeted by Link are some of the future prescribers for Archimedes' late stage portfolio, including the phase III product, Nasalfent, intranasal fentanyl for rapid relief of breakthrough cancer pain.